US Edition
India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply - Novo Nordisk (NYSE:NVO)
Indian generics launched over 50 semaglutide brands at up to 80% discount after patent expiry, targeting domestic use and exports to multiple countries.
- Over the weekend, at least five domestic drugmakers launched generic versions of Novo Nordisk's GLP-1 weight-loss drugs in India, undercutting original prices by up to 80% following the expiration of the Indian patent on Friday.
- India, known as 'the world's pharmacy,' is a critical market with around 100 million people living with diabetes, making it a priority for generic manufacturers preparing to launch over 50 affordable variants.
- Sun Pharmaceutical launched generic semaglutide for as low as 750 rupees weekly, while Natco Pharma and Alkem Laboratories offer monthly prices starting at 1,250 rupees and 1,800 rupees respectively.
- Novo Nordisk India maintains retail prices between 8,800 and 10,000 rupees, and analysts suggest the Danish drugmaker could retain significant market share by maintaining a 15% to 20% premium over generic versions.
- Export-Focused Dr. Reddy's Laboratories plans to expand semaglutide sales to Canada, Turkey, and Brazil this year, while consultants expect more than 50 brands to launch globally in coming months.
14 Articles
14 Articles
Health Innovations and Market Movements: A Confluence of Cultures
The Vatican allows Catholics to receive organ transplants from genetically modified animals, respecting medical ethics. Manipal Health plans a $1.2 billion IPO in India. Gilead acquires Ouro Medicines for immune disorder drug expansion. Indian firms release cheaper Novo drug versions. Oryon launches Parkinson's therapy with new funding.
'Weight Loss Drugs Serious Medicines for Serious Problem, Shouldn't Be Used Recklessly,' Warns AIIMS Expert
Get latest articles and stories on India at LatestLY. The generic semaglutide has entered the Indian market at a huge discount compared to innovator products already available, according to an expert from AIIMS, Dr Nikhil Tandon, professor and HOD of the Department of Endocrinology and Metabolism. India News | 'Weight Loss Drugs Serious Medicines for Serious Problem, Shouldn't Be Used Recklessly,' Warns AIIMS Expert.
India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply - Novo Nordisk (NYSE:NVO)
India's drugmakers roll out low-cost copies for Novo Nordisk's semaglutide, slashing prices up to 70% as analysts weigh global market disruption risks. Importance Rank: 1
In recent months various weight loss drugs have become popular, which promise not to bounce, however, their cost is usually very high, so pharmaceuticals have launched more accessible options in generic drugs, in El Heraldo de México we share the details. Medications that promise to lose weight ...
Coverage Details
Bias Distribution
- 80% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
